New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The new analysis was published online as part of ACR Convergence 2020.

SENSCIS-ON is an open-label extension trial to assess the long-term safety of nintedanib in patients with SSc-ILD who completed the Phase III SENSCIS® trial. The study is evaluating the absolute and relative change from baseline in the forced vital capacity (FVC) as a measure of lung function over 52 weeks.

The interim analysis showed that the safety profile of nintedanib in SENSCIS-ON was consistent with that reported over 52 weeks in the SENSCIS trial with diarrhea being the most frequently reported adverse event.The analysis showed that 347 patients in the extension study who received nintedanib demonstrated a decrease in FVC over 52 weeks as did patients in the SENSCIS study. The average change in FVC from baseline to week 52 of SENSCIS-ON was −51.3 mL in all patients treated in SENSCIS-ON, while the change from baseline to week 52 in the SENSCIS trial was −42.7 mL.

“Boehringer Ingelheim is continuously committed to providing scientific data, offering clinicians more confidence in treating patients with SSc-ILD,” commented Dr. Susanne Stowasser, Associate Medical ​Head Pulmonology ​at Boehringer Ingelheim. “We are thrilled to share the new data demonstrating a similar consistent safety profile of nintedanib in people living with SSc-ILD and suggesting a sustained effect in slowing lung function decline.”

Tags : #BoehringerIngelheim #nintedanib #interstitiallungdisease #DrSusanneStowasser #SSc-ILD

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026